TABLE 2.
Base-case cost-effectiveness results.
| Treatment strategy | Cost, CNY | QALY | ICER, CNY | VBP, CNY a | ||
|---|---|---|---|---|---|---|
| Total | Incremental | Total | Incremental | |||
| Discounted net price, therapeutic effect based on HRs of clinical endpoints | ||||||
| Statins therapy alone | 400,705 | NA | 7.22 | NA | NA | NA |
| Alirocumab added to statins therapy | 871,321 | 470,616 | 7.51 | 0.29 | 1,613,997 | 6,071 |
| Full list price, therapeutic effect based on HRs of clinical endpoints | ||||||
| Statins therapy alone | 400,705 | NA | 7.22 | NA | NA | NA |
| Alirocumab added to statins therapy | 1,119,465 | 718,760 | 7.51 | 0.29 | 2,465,017 | 6,071 |
| Discounted net price, therapeutic effect based on RRs of LDL-C reduction | ||||||
| Statins therapy alone | 400,705 | NA | 7.22 | NA | NA | NA |
| Alirocumab added to statins therapy | 842,176 | 441,471 | 7.77 | 0.55 | 805,795 | 11,861 |
| Full list price, therapeutic effect based on RRs of LDL-C reduction | ||||||
| Statins therapy alone | 400,705 | NA | 7.22 | NA | NA | NA |
| Alirocumab added to statins therapy | 1,090,320 | 689,615 | 7.77 | 0.55 | 1,258,721 | 11,861 |
CNY, Chinese Yuan; HR, hazard ratio; ICER, incremental cost-effectiveness ratio; LDL-C, low-density lipoprotein cholesterol; NA, not applicable; QALY, quality-adjusted life-year; RR, relative risk; VBP, value-based price
a
VBP was defined as an estimated expected price to meet the ICER of 212,676 CNY per QALY gained